On the stock market since 2000, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 40% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The stock trades below its recent peak — about 12% off the top. A pullback, not a collapse.
Sales run at $10.0M a year. A small number, but proof the product has real buyers.
It pays out $0.53 per share each year — regular cash for whoever holds the stock.
A loss of $2.8M against $10.0M in annual sales. And on top of that, sales fell from the year before.
On our five-subject report card, SMMOX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SMMOX is a high-risk stock — not yet profitable, and its future rides on its product catching on.